Core Viewpoint - Eddie Pharmaceuticals announced the results of its key Phase III clinical study for the first "three-in-one" anti-HIV single-tablet combination innovative drug, Ainomit (Fubangde, ALT), which has been published in the prestigious medical journal BMC Medicine [1] Group 1 - The clinical study results were part of the SPRINT96 week extension trial for the treated conversion population [1] - BMC Medicine is a top-tier journal in the JCR and Chinese Academy of Sciences classification, with a five-year impact factor of 9.4 [1] - The published metrics of this study have already surpassed those of imported similar products [1]